Author

E. Orouji

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:ChIP-seq· 3 Research Focus:chromatin & epigenetic regulation· 3 Approach:experimental assay· 3 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

K. Rai· 4 shared M. Maitituoheti· 4 shared M. Tang· 4 shared C. Terranova· 3 shared J. Schulz· 3 shared A. K. Ghosh· 2 shared A. Raman· 2 shared A. T. Raman· 2 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

K. Rai

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A primary patient-derived model for investigating functional heterogeneity within the human Leukemic Stem Cell Compartment

H. Boutzen, M. Chan-Seng-Yue, A. Murison, N. Mbong, E. Wagenblast, C. Arlidge, S. A. Madani Tonekaboni, E. Orouji, A. Arruda, A. Mitchell, F. Notta, M. Lupien, M. Minden, K. Kaufmann, J. Dick

bioRxiv · Mar 1, 2022 · PreprintCancer Biology

H3K4me1-marked Enhancer Activation in Resistant Prostate Cancers Implicates SOX4 and MENIN Inhibition as Therapeutic Strategies

C. Terranova, M. Maitituoheti, A. T. Raman, M. Tang, N. E. Anvar, A. K. Ghosh, S. B. Amin, J. Schulz, E. Orouji, F. Giancotti, P. Troncoso, C. J. Logothetis, T. Thompson, K. Rai

The paper identifies H3K4me1-marked enhancers in therapy-resistant prostate cancers and suggests SOX4 and MENIN inhibition as therapeutic strategies.

bioRxiv · Sep 2, 2021 · PreprintCancer Biology

Chromatin State Dynamics Confers Specific Therapeutic Strategies in Enhancer Subtypes of Colorectal Cancer

E. Orouji, A. T. Raman, A. K. Singh, A. Sorokin, E. Arslan, A. K. Ghosh, J. Schulz, C. J. Terranova, M. Tang, M. Maitituoheti, S. C. Callahan, K. J. Tomczak, Z. Jiang, J. S. Davis, S. Ghosh, , K. Rai

This study identifies enhancer subtypes in colorectal cancer through epigenomic analysis and proposes targeted therapeutic strategies based on these subtypes.

bioRxiv · Sep 4, 2020Cancer Biology

Bivalent and Broad Chromatin Domains Regulate Pro-metastatic Drivers in Melanoma

C. Terranova, M. Tang, M. Maitituoheti, A. Raman, J. Schulz, S. Amin, E. Orouji, K. Tomczak, S. Sarkar, J. Oba, C. Creasy, C.-J. Wu, D. Zhao, K. Chen, L. E. Haydu, , K. Rai

The paper identifies bivalent chromatin states and broad H3K4me3 domains associated with pro-metastatic drivers in melanoma using ChIP-sequencing data from tumor samples and cell lines.

bioRxiv · Aug 1, 2019 · PreprintCancer Biology

Enhancer Reprogramming Confers Dependence on Glycolysis and IGF signaling in KMT2D Mutant Melanoma

M. Maitituoheti, E. Keung, M. Tang, L. Yan, H. Alam, G. Han, A. Raman, C. Terranova, S. Sarkar, E. Orouji, S. Amin, S. Sharma, M. Williams, N. S. Samant, M. Dhamdhere, , K. Rai

This study identifies KMT2D as a tumor suppressor in melanoma, showing its loss leads to metabolic reprogramming toward glycolysis and dependence on IGF signaling, suggesting therapeutic targeting of these pathways.

bioRxiv · Dec 27, 2018Cancer Biology